Zynex Medical Electrotherapy Pain Management and Growth Strategy

EBITDA Reconciliation - 2021 Adjusted EBITDA: Net income Depreciation and Amortization* $ Stock-based compensation expense Restructuring/severance** Interest expense and other, net Income tax expense Adjusted EBITDA % of Net Revenue For the Three Months Ended March 31, 2021 2020 (706) $ 2,937 268 68 108 497 318 9 4 (384) (483) $ (387) $ 3,023 (2%) 20% ZYNEX MEDICAL" 24 24

View entire presentation